SCHEDULE 13G/A: Biotechnology Value Fund Discloses Celcuity Stake
Beneficial Ownership Disclosure
Biotechnology Value Fund and its affiliates reported a combined 1.6% passive beneficial ownership stake in Celcuity Inc. as of September 30, 2025.
Summary
- Biotechnology Value Fund, L.P. (BVF) and its affiliated entities, including BVF I GP LLC, Biotechnology Value Fund II, L.P. (BVF2), BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP Holdings LLC, BVF Partners L.P., BVF Inc., and Mark N. Lampert, collectively reported beneficial ownership in Celcuity Inc.
- As of September 30, 2025, the aggregate beneficial ownership by Partners, BVF Inc., and Mr. Lampert was 658,421 shares, representing approximately 1.6% of Celcuity Inc.'s outstanding common stock.
- This percentage is based on 42,426,711 shares outstanding as of August 7, 2025, as reported in Celcuity Inc.'s Form 10-Q.
- The filing states that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, except for activities related to a nomination under Rule 14a-11.
- Individual beneficial ownerships include: BVF with 340,278 shares (0.8%), BVF2 with 268,775 shares (0.6%), and Trading Fund OS with 36,270 shares (0.09%).
- BVF GP Holdings LLC beneficially owned 609,053 shares (1.4%), representing the aggregate of BVF and BVF2 holdings.
Sentiment
Score: 5
Explanation: Neutral. This is a routine disclosure of a passive ownership stake by an institutional investor, providing no direct positive or negative operational or financial news about the issuer.
Positives
- An institutional investor, Biotechnology Value Fund, maintains a significant, albeit passive, stake in Celcuity Inc., which could be seen as a vote of confidence in the company's long-term prospects.
Future Outlook
NA
Industry Context
This filing indicates continued institutional interest in Celcuity Inc., a biotechnology company. Biotechnology Value Fund specializes in the biotechnology sector, suggesting their investment aligns with their sector focus.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, potentially offering some reassurance or insight into institutional interest.
Key Dates
| Date | Description |
|---|---|
| 2025-08-07 | Date of total shares outstanding calculation (42,426,711 shares) as reported in Issuer's Form 10-Q. |
| 2025-08-14 | Date Issuer's Quarterly Report on Form 10-Q was filed with the SEC. |
| 2025-09-30 | Date of event which requires filing of this statement; beneficial ownership calculated as of this date. |
| 2025-11-14 | Date the Schedule 13G/A filing was signed and filed. |
Keywords
Celcuity Inc., Biotechnology Value Fund, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, Biotechnology, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.